HAEi global access program for Ruconest now live

Dutch biotech firm Pharming Group (Euronext: PHARM) and the UK’s Clinigen Group (LSE: CLIN) are collaborating to provide access to Pharming’s Ruconest (conestat alfa) and say the program is now live. The unique access program was initiated by HAEi, the International Patient Organization for C1- Inhibitor Deficiencies.

Ruconest is a recombinant human C1- inhibitor, approved by the European Medicines Agency and US Food and Drug Administration for the treatment of acute attacks of hereditary angioedema (HAE). The “HAEi GAP” program enables patients in all countries where Ruconest is not commercially available to gain access to the drug through an ethical and regulatory compliant “Named Patient Program” mechanism.

“HAEi is committed to securing access to HAE medications for patients across the globe,” said Anthony Castaldo, president of HAEi, adding: “We are extremely proud to have established HAEi GAP with our current partners and to be able to announce that, from today, physicians are able to request RUCONEST to meet the needs of their patients.”